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ABSTRACT
Aims To assess (1) how far the efﬁcacies of front-line smoking cessation pharmacotherapies vary as a function of smoker
characteristics and (2) associations between these characteristics and success of smoking cessation attempts.
Design Prospective correlational study in the context of a double-blind randomized trial. The outcome was regressed
individually onto each covariate after adjusting for treatment, and then a forward stepwise model constructed. Treatment
moderator effects of covariates were tested by treatment × covariate interactions. Setting Health service facilities in
multiple countries. Participants Data came from 8120 smokers willing to make a quit attempt, randomized to
varenicline, bupropion, nicotine replacement therapy (NRT) or placebo in Evaluating Adverse Events in a Global Smoking
Cessation Study (EAGLES) between 30 November 2011 and 13 January 2015.Measurements Smoker characteristics
measured at baseline were country, psychiatric history, sex, age, body mass index (BMI), ethnic group, life-time suicidal
ideation/behaviour, anxiety, depression, aggression, psychotropic medication, history of alcohol/substance use disorder,
age of starting smoking, cigarette dependence [Fagerström Test for Cigarette Dependence (FTCD)] and prior use of study
medicines. Outcome was biochemically conﬁrmed continuous abstinence at weeks 9–24 from start of treatment.
Findings No statistically signiﬁcant treatment × covariate interactions were found. Odds of success were associated
independently positively with age [odds ratio (OR) = 1.01; 95% conﬁdence interval (CI) = 1.00, 1.01], BMI (1.01; 95%
CI = 1.00, 1.02) and age of starting smoking (1.03; 95% CI = 1.02, 1.04). Odds were associated independently negatively
with US (versus non-US) study site (0.53; 95% CI = 0.46, 0.61), black (versus white) ethnic group (0.57; 95% CI = 0.45,
0.72), mood disorder (0.85; 95% CI = 0.73, 0.99), anxiety disorder (0.71; 95% CI = 0.55, 0.90) and psychotic disorder
(0.73; 95% CI = 0.50, 1.07), taking psychotropic medication (0.81; 95% CI = 0.68, 0.95), FTCD (0.89; 95% CI = 0.87,
0.92) and previous use of NRT (0.78; 95% CI = 0.67, 0.91). Conclusions While a range of smoker characteristics—in-
cluding psychiatric history, cigarette dependence and prior use of nicotine replacement therapy (NRT)—are associated
with lower cessation rates, they do not substantially inﬂuence the efﬁcacy of varenicline, bupropion or NRT.
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INTRODUCTION
Evaluating Adverse Events in a Global Smoking Cessation
Study (EAGLES; NCT01456936) was a large, multi-
centre, randomized, placebo-controlled trial that exam-
ined the safety and efﬁcacy of varenicline, bupropion
and transdermal nicotine patch [a form of nicotine
replacement therapy (NRT)] for smoking cessation [1].
The size of the trial, randomizing smokers in a triple-
dummy fashion into three active treatments and placebo,
including smokers from multiple countries with varying
psychiatric histories, and gathering data on a wide range
of smoker characteristics provided an unparalleled
opportunity to assess how smoker characteristics predict
smoking cessation outcomes and how they may inﬂuence
treatment efﬁcacy.
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It is important to accumulate information on smoker
characteristics that inﬂuence the success of stopping
smoking. Evidence suggests that older age and markers
of lower cigarette dependence are predictive of success
[2–6], although not all studies show these results [7].
There is less consistent, conﬂicting or negative evidence
on the effects of age of smoking onset [2,3], substance
use disorder [8], psychiatric disorder [6,9], gender
[4,6,10], geographical location [11,12], body mass index
(BMI) [2,3,10,13,14] and prior use of smoking cessation
treatments [15]. These covariates were assessed in the
EAGLES trial. It was reported in the main outcome paper
that psychiatric history (versus no history) was associated
with lower success rates and that this variable did not in-
teract with treatment efﬁcacy [1]. However, the predictive
effects of other variables assessed have not been reported.
With such a large and diverse sample receiving a variety
of treatments and a substantial number receiving placebo,
the EAGLES trial can add signiﬁcantly to our knowledge to
help buildmodels of cigarette addiction and assist clinicians
in treating this disorder.
Clinically, it is important to know how treatment efﬁ-
cacy varies as a function of smoker characteristics. Moder-
ators of treatment efﬁcacy have not been studied widely in
randomized clinical trials (RCTs), but some evidence is
emerging. A recent meta-analysis found that varenicline
was more effective for female than for male smokers for
short- to medium-term cessation (up to 6 months) [16].
Smokers with a faster rate of nicotine metabolism appear
to be less successful when using nicotine patches than
those with a slower metabolism [17]. A placebo-controlled
RCT of nicotine nasal spray appeared to show greater efﬁ-
cacy in more addicted smokers [18]. One study found that
smokers with a psychiatric disorder beneﬁted more from
‘dual form’ NRT (transdermal patch plus a faster-acting
product) versus no NRT than those without a psychiatric
disorder [19]. A study of methylphenidate to aid smoking
cessation in smokers with attention deﬁcit hyperactivity
disorder reported in a post-hoc analysis an effect only in
those smokers with more severe symptoms [20]. A post-
hoc analysis of two RCTs of NRT found reduced efﬁcacy in
overweight women [21]. It has been proposed that female
smokers may not respond as well to NRT or bupropion as
male smokers [22]. A genome-wide association study failed
to identify speciﬁc associations with NRT treatment
efﬁcacy, but the results were reported to be suggestive of
speciﬁc regions that merit further scrutiny [23].
On common sense grounds, one may hypothesize that
smokers who have used a given form of treatment in the
past may beneﬁt less from that treatment because their
past failure is indicative of treatment resistance. However,
a placebo-controlled RCT of varenicline in smokers who
had used this drug previously found effect sizes similar to
those in a study of drug-naive smokers [15].
Very little research has been undertaken on smoker
characteristics that may moderate relative effectiveness of
different forms of treatment compared with each other. In
clinical practice in the United Kingdom, the relative
efﬁcacy of varenicline and NRT has been found to vary
throughout different local services [24], but the service
characteristics that underlie this are not known. Some ev-
idence suggests that varenicline is more effective than NRT
in smokers with ‘normal’ rates of nicotine metabolism, but
not in thosewhometabolize nicotine slowly [25]. However,
the relative efﬁcacy of different pharmacotherapies as a
function of other phenotypes has not been studied. Such
research is difﬁcult because it requires large sample sizes
and randomization to multiple active treatments.
This study aimed to assess (1) how far the efﬁcacy of the
pharmacotherapies tested varied as a function of smoker
characteristics and (2) associations of those characteristics
with odds of smoking abstinence taking account of
pharmacotherapy.
METHODS
Design
EAGLES was a randomized (1 : 1 : 1 : 1), double-blind,
triple-dummy, placebo- and active- (nicotine patch, NRT;
21 mg/day with taper) controlled trial of varenicline
(1 mg twice daily) and bupropion (150 mg twice daily)
for 12 weeks with 12-week non-treatment follow-up. All
subjects received repeated brief smoking cessation counsel-
ling. The published trial report provides full details of the
study design and efﬁcacy outcome measures, and continu-
ous abstinence at the end of treatment (weeks 9–12) and
to the end of the study (weeks 9–24) [1]. The trial protocol
is registered with http://clinicaltrials.gov (NCT01456936).
This paper reports an exploratory analysis to assess pre-
dictors of abstinence and interactions between study drug
and smoker variables on carbon monoxide-veriﬁed
smoking abstinence from weeks 9 to 24 after treatment
initiation. We used weeks 9–24 (a period that includes
the last 4 weeks of treatment and 12-week non-treatment
follow-up) as this provided a measure that is closest to the
Russell Standard, the recommended end-point to ensure
greatest conﬁdence in extrapolating to life-time abstinence
[26]. Following the Russell Standard, those failing to record
primary outcome data were classiﬁed as continuing
smokers.
Participants
Participants in EAGLES were male and female smokers,
aged 18–75 years, with and without pre-speciﬁed psychi-
atric diagnoses who smoked an average of ≥ 10
cigarettes/day. They were recruited from 16 countries. A
list of participating study sites was published previously
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[1]. Supporting information, Table S1 details subject enrol-
ment and site presence by country/region by treatment.
The sample included smokers with psychotic, anxiety
and mood disorders meeting the Diagnostic and Statistical
Manual of Mental Disorders, 4th edn, text revision diagnos-
tic criteria conﬁrmed by Structured Clinical Interview for
Diagnostic and Statistical Manual of Mental Disorders, Axis I
and Axis II disorders (SCID-I and SCID-II) [27], without
clinical exacerbation in the prior 6 months, with stable
treatment (medication and dose) for ≥ 3 months (if on
treatment) and not judged to be at imminent risk of self-
injurious or suicidal behaviour.
A total of 8120 subjects were included in the present
analyses (varenicline, n = 2030; bupropion, n = 2029;
NRT, n = 2029; placebo, n = 2032). Twenty-four partici-
pants with borderline personality disorder were excluded
because the small size of this group did not permit accurate
modelling involving this disorder. The sample was not
powered to detect interactions between treatment group
and smoker characteristics, and the analyses were not
pre-planned and thus should be considered exploratory.
Smoker characteristics
The smoker characteristics examined were: country of
study site (USA versus non-USA); history of psychiatric
diagnosis (deﬁned as the primary diagnosis: none, mood
disorder, anxiety disorder, psychotic disorder); sex; age;
BMI; ethnic group (white, black, other); lifetime suicidal
ideation and/or behaviour [none versus any, captured
through Columbia–Suicide Severity Rating Scale (C-SSRS)]
[28]; anxiety score [Hospital Anxiety and Depression scale
(HADS)] [29]; depression score (HADS) [29]; aggression
score [Buss–Perry Aggression Questionnaire (BPAQ)]
[30]; use of psychotropic medication, including sleeping
aids (none, any); cigarette dependence [Fagerström Test
for Cigarette Dependence (FTCD)] [31]; age of starting
smoking; and prior use of study medicines (none versus
any, for each of the three medications—varenicline,
bupropion or any type of NRT). Supporting information,
Table S2 describes the collection of smokers’ characteristics
as recorded on the patient report form used by
investigators.
Statistical analyses
The data analysis involved a series of logistic regressions,
with continuous abstinence fromweeks 9 to 24 as the out-
come measure. The analyses did not include study site as a
level or factor because of the large number of sites with
many contributing no participants. The effect of each
individual covariate was studied using logistic regression
controlling for the treatment effect, while also including
the treatment × covariate interaction (model 1). As this
model does not allow for potential collinearity between
covariates, all covariates were entered into a forward step-
wise logistic regression model that controlled for the treat-
ment effect, retaining a covariate until no signiﬁcant
improvement in the model ﬁt was seen using a threshold
of P = 0.05 (model 2). Additional analyses were performed
by categorizing the numerical covariates in model 1 to
facilitate the interpretation of these covariate effects.
RESULTS
Table 1 shows the sample characteristics of the four treat-
ment groups and their similarities.
The odds ratios (ORs) for active treatment versus
placebo, the results of themodel 1 analysis for all covariates
entered singly and the results of the stepwise model 2
analysis are shown in Table 2.
The ORs for continuous abstinence weeks 9–24 for
active treatment versus placebo based on the stepwise
model were 2.84 [95% conﬁdence interval (CI) = 2.35,
3.42] for varenicline, 1.96 (95% CI = 1.61, 2.38) for
bupropion and 1.86 (95% CI = 1.53, 2.27) for NRT. From
the stepwise model, abstinence was associated positively
and independently with non-US study site; higher age;
higher BMI; white versus black race/ethnicity; not having
a history of mood, anxiety or psychotic disorder; not taking
psychotropic medication; lower cigarette dependence; not
previously having used NRT; and higher age of starting
smoking. Data in Table 2 also show that no treatment × co-
variate interactions added signiﬁcantly to the prediction
above the main effect for that covariate.
The percentages abstinent and the ORs stratiﬁed by
covariate categories and treatment are presented in
Table 3 (baseline demographic and smoking covariates)
and Table 4 (baseline psychiatric history covariates).
Results indicate that ORs for treatment versus placebo
comparisons were consistent across different values of co-
variates, with larger deviations limited to strata with small
sample sizes.
DISCUSSION
The ﬁndings of these analyses are consistent with prior ev-
idence showing lower chances of success of quit attempts
in smokers with higher levels of cigarette addiction, poorer
mental health and younger age, making it clear that these
associations are independent of each other and indepen-
dent of other putative covariates. Pharmacotherapy did
not inﬂuence this vulnerability, but rather improved absti-
nence rates across the board. Overall, varenicline almost
tripled—and bupropion and NRT almost doubled—the
odds of quitting versus placebo at 6 months, and the treat-
ment × covariate interactions were not signiﬁcant. These
ﬁndings also provide the clearest evidence to date that
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younger age of starting to smoke and US origin are associ-
ated with lower success rates of stopping regardless of
treatment, even after controlling for other covariates. The
ﬁndings also provide suggestive evidence, once other covar-
iates have been adjusted for, that smokers with higher BMI
may have a greater likelihood of success of stopping. Those
who have used any form of NRT in the past may have a
lower likelihood of success overall. However, prior use of a
given pharmacotherapy did not appear to reduce the im-
pact of that or another pharmacotherapy in a given quit
attempt.
The fact that varenicline, bupropion and NRT were all
effective in smokers with mental health problems, assessed
with a number of variables (e.g. diagnostic history, HADS,
use of psychotropic medication), and their relative efﬁcacy
was similar to that in smokers without a psychiatric his-
tory, is clinically important. Part of the reluctance of
clinicians to treat cigarette addiction in patients with men-
tal health problems may stem from a lack of conﬁdence
that it would be helpful. This concern can now be dispelled,
even in smokers with psychotic disorders.
The apparent absence of interactions between treat-
ment type and smokers’ baseline characteristics, despite
the large sample size and wide range of characteristics
assessed, suggests that clinicians should always encourage
smokers to use what is, on average, themost effective treat-
ment option rather than attempting to match smokers to
treatments by any of the variables assessed. In particular,
the ﬁnding that pharmacotherapy efﬁcacy did not appear
to be affected by prior use of that treatment (Table 3) has
important implications for clinical practice, but it seems
to conﬂict with an observational study which found that
smokers who switched to a different pharmacotherapy in
a subsequent quit attempt were more likely to succeed in
the short term than those who persisted with the one used
previously [32]. That was a correlational study and
involved smokers making a decision to switch rather than
being randomized to a medicine they may or may not have
used previously. EAGLES shows that such a switch might
not be necessary and in fact might be counter-productive
if it means switching from a more to less effective
pharmacotherapy.
Table 1 Sample characteristics.
Varenicline Bupropion NRT Placebo All
Covariate (n = 2030) (n = 2029) (n = 2029) (n = 2032) (n = 8120)
Age, years 46.53 (12.35) 46.28 (12.63) 46.87 (12.14) 46.43 (12.17) 46.53 (12.33)
Age of starting smoking, years 18.16 (5.77) 18.10 (5.95) 18.31 (6.06) 18.20 (5.99) 18.19 (5.94)
Female 1118 (55.1%) 1128 (55.6%) 1143 (56.3%) 1147 (56.4%) 4536 (55.9%)
Ethnic group
White 1676 (82.6%) 1655 (81.6%) 1640 (80.8%) 1655 (81.4%) 6626 (81.6%)
Black 284 (14.0%) 285 (14.0%) 309 (15.2%) 283 (13.9%) 1161 (14.3%)
Other 70 (3.4%) 89 (4.4%) 80 (3.9%) 93 (4.6%) 332 (4.1%)
Country
USA 1065 (52.5%) 1067 (52.6%) 1061 (52.3%) 1065 (52.4%) 4258 (52.4%)
Non-USA 965 (47.5%) 962 (47.4%) 968 (47.7%) 967 (47.6%) 3862 (47.6%)
BMI, kg/m2 28.13 (6.41) 28.13 (6.43) 27.98 (6.29) 28.28 (6.39) 28.13 (6.38)
History of psychiatric diagnosis
None 1005 (49.5%) 1001 (49.3%) 1013 (49.9%) 1009 (49.7%) 4028 (49.6%)
Mood disorder 734 (36.2%) 729 (35.9%) 721 (35.5%) 726 (35.7%) 2910 (35.8%)
Anxiety disorder 196 (9.7%) 201 (9.9%) 196 (9.7%) 199 (9.8%) 792 (9.8%)
Psychotic disorder 95 (4.7%) 98 (4.8%) 99 (4.9%) 98 (4.8%) 390 (4.8%)
Alcohol/substance use disorder history 228 (11.2%) 243 (12.0%) 235 (11.6%) 245 (12.1%) 951 (11.7%)
HADS anxiety score 3.93 (3.52) 4.00 (3.67) 3.94 (3.57) 4.05 (3.49) 3.98 (3.56)
HADS depression score 2.36 (2.89) 2.44 (3.02) 2.34 (2.85) 2.35 (2.76) 2.37 (2.88)
C-SSRS prior suicidal ideation and/
or behaviour
400 (19.7%) 409 (20.2%) 388 (19.1%) 411 (20.2%) 1608 (19.8%)
BPAQ aggression score 54.75 (16.93) 55.26 (17.41) 56.03 (17.78) 55.58 (17.18) 55.40 (17.33)
Baseline psychotropic medication 687 (33.8%) 629 (31.0%) 647 (31.9%) 654 (32.2%) 2617 (32.2%)
FTCD 5.77 (1.97) 5.79 (1.99) 5.76 (1.97) 5.71 (2.02) 5.76 (1.99)
Prior varenicline use 286 (14.1%) 348 (17.2%) 331 (16.3%) 306 (15.1%) 1271 (15.7%)
Prior bupropion use 211 (10.4%) 221 (10.9%) 206 (10.2%) 206 (10.1%) 844 (10.4%)
Prior any NRT use 523 (25.8%) 539 (26.6%) 544 (26.8%) 526 (25.9%) 2132 (26.3%)
NRT = nicotine replacement therapy (transdermal nicotine patch); BMI = body mass index; HADS = Hospital Anxiety and Depression Scale; C-SSRS =
Columbia-Suicide Severity Rating Scale; BPAQ = Buss–Perry Aggression Questionnaire; FTCD = Fagerström Test for Cigarette Dependence; SD = standard de-
viation. Data are mean (SD) or n (%).
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However, of concern is the ﬁnding that past use of NRT
in the stepwise model and past use of any of the treatments
in the simple model were associated with lower success
rates overall (Table 2). In the case of NRT, lower success
rate was not accounted for by cigarette addiction or other
covariates as measured. It remains possible, however, that
it reﬂects the impact of unmeasured residual confounding.
This could be an aspect of cigarette addiction that is not
captured adequately by the FTCD or some other factor. In
the context of ﬁndings in the electronic cigarette
Table 2 Predictors and moderators of abstinence during weeks 9–24 (univariate analysis, model 1 and stepwise regression analyses,
model 2).
Model 1
(univariate)a
P-value for treatment × covariate
interaction (testing for treatment
moderation)
Model 2
(stepwise)b
Treatment
Varenicline versus placebo 2.70 (2.25–3.25) – 2.84 (2.35–3.42)
Bupropion versus placebo 1.88 (1.56–2.28) – 1.96 (1.61–2.38)
NRT versus placebo 1.81 (1.50–2.20) – 1.86 (1.53–2.27)
Covariate
Country – 0.8235 –
USA versus non-USA 0.48 (0.42–0.55) – 0.53 (0.46–0.61)
Psychiatric diagnosis – 0.6290 –
Mood disorder versus no diagnosis 0.73 (0.64–0.84) – 0.85 (0.73–0.99)
Anxiety disorder versus no diagnosis 0.61 (0.48–0.78) – 0.71 (0.55–0.90)
Psychotic disorder versus no diagnosis 0.48 (0.33–0.70) – 0.73 (0.50–1.07)
Age, years – 0.1756 –
1-year increase 1.01 (1.00–1.03) – 1.01 (1.00–1.01)
Age of starting smoking, years – 0.5624 –
1-year increase 1.04 (1.02–1.06) – 1.03 (1.02–1.04)
Gender – 0.5794 Dropped
Female versus male 0.97 (0.85–1.10) – –
Ethnic group – 0.3421 –
Black versus white 0.42 (0.33–0.53) – 0.57 (0.45–0.72)
Other versus white 0.74 (0.52–1.06) – 0.83 (0.60–1.15)
BMI, kg/m2 – 0.6027 –
1-unit increase 0.99 (0.96–1.01) – 1.01 (1.00–1.02)
Alcohol/substance use disorder history – 0.8222 Dropped
Yes versus no 0.69 (0.55–0.85) – –
HADS anxiety score – 0.3222 Dropped
1-unit increase 0.93 (0.89–0.98) – –
HADS depression score – 0.2031 Dropped
1-unit increase 0.93 (0.88–0.99) – –
C-SSRS prior suicidal ideation or behaviour – 0.6296 Dropped
Yes versus no 0.74 (0.63–0.88) – –
BPAQ aggression score – 0.0666 Dropped
1-unit increase 1.00 (0.99–1.01) – –
Baseline psychotropic medication – 0.2465 –
Yes versus no 0.68 (0.59–0.78) – 0.81 (0.68–0.95)
FTCD – 0.3703 –
1-unit increase 0.85 (0.79–0.92) – 0.89 (0.87–0.92)
Prior use of varenicline – 0.6799 Dropped
Yes versus no 0.78 (0.64–0.93) – –
Prior use of bupropion – 0.6226 Dropped
Yes versus no 0.80 (0.64–0.99) – –
Prior use of NRT – 0.8185 –
Yes versus no 0.69 (0.59–0.80) – 0.78 (0.67–0.91)
NRT = nicotine replacement therapy (transdermal nicotine patch; BMI = bodymass index; HADS = Hospital Anxiety and Depression Scale; C-SSRS = Colum-
bia-Suicide Severity Rating Scale; BPAQ= Buss–Perry Aggression Questionnaire; FTCD= Fagerström Test for Cigarette Dependence; OR= odds ratio; CI = con-
ﬁdence interval. Data are OR (95% CI), unless stated otherwise. aModel 1: treatment included in model plus each other covariate on its own and the
treatment × covariate interaction; bmodel 2: ﬁnal model included treatment plus other covariates added stepwise until no further signiﬁcant improvement
in ﬁt.
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literature—that past use of these devices is associated with
reduced rates of smoking cessation but not reduced quit at-
tempt rates [33]—the present ﬁndings raise the possibility
that use of nicotine in a form other than smoking may, for
an as yet unknown reason, reduce the ability of smokers to
stop smoking. Given the widespread use of nicotine prod-
ucts by smokers, this association is worthy of further
research.
The lower success rates in US smokers compared with
those in other countries is in line with informal cross-study
comparisons. The ﬁndings tend to support the view that
smokers in countries such as the United States have
reached a point in the tobacco epidemic where the
relatively low proportion of people who continue to smoke,
despite strong cultural pressures not to, have particular
characteristics that make it more difﬁcult for them to stop.
The lower success rate in the United States versus other
smokers was not attenuated in the stepwise model,
suggesting that other factors may explain the country
differences.
The lower success rate among black smokers has been
observed in other studies in the United States [34]. Because
ethnic difference remained in the stepwise model suggests
that factors other than cigarette addiction and other
measured vulnerabilities are responsible. This, too, is an
important area of future study.
No difference was observed between male and female
smokers in terms of success rates for smoking cessation.
This observation is in accordance with population-level
studies [4], but is at variance with some clinical studies
[16]. It is unclear why some studies ﬁnd sex differences
while others do not. It seems unlikely to be due to sampling
variation. To our knowledge, no attempt has been made to
identify moderators of potential sex differences. Doing so
could provide important insights into cigarette addiction
and would be worthwhile.
One surprising result was the emergence of BMI as be-
ing associated positively with success in the stepwise
model. The effect size was small, and it is possible that this
represents a Type 1 error. However, it suggests that future
studies examine this association to clarify any relationship.
These analyses had a number of limitations. First, the
analyses were not pre-planned or registered. While, during
the development of the EAGLES trial, it was intended to
examine predictors of success and treatment moderators,
such analyses are often not performed following RCTs,
which raises the risk of reporting bias. There is amovement
to require pre-speciﬁcation of all hypothesis-testing studies,
but currently it is not standard practice. Until it is, and until
there is ready access to such registrations, all ﬁndings from
correlational analyses must be viewed with caution.
Another limitation is that even though EAGLES was a
large study, the sample sizes in some strata were relatively
small. It therefore remains possible that these analysesTa
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did not detect predictive or moderator relationships that
were present. It is unlikely that a smoking cessation
pharmacotherapy evaluation of this size and scope will be
conducted again in the next decade or so. This means that
identifying such relationships will rely upon aggregating
across studies. This, in turn, means that researchers must
report their ﬁndings in a way that will permit aggregation,
or preferably make their data available for synthesis.
A third limitation relates to the categories used for some
of the covariates; thus, it was necessary to pool all non-US
smokers. Clearly, there will be considerable heterogeneity
among this group, which must temper conclusions about
the US versus non-US comparison. Additionally, the psychi-
atric disorder classiﬁcation was relatively broad, and it may
be that there is heterogeneity within the categories used.
In conclusion, the EAGLES study conﬁrmed that youn-
ger age, higher level of cigarette addiction and psychiatric
disorder independently predict failure to achieve continu-
ous abstinence. It found that lower age of starting to
smoke, use of psychotropic medication, having used NRT
previously, being in the United States (versus non-USA)
and being black (versus white) were also associated inde-
pendently with lack of success in stopping smoking and
that high BMI appeared to be predictive of success at stop-
ping. Importantly, it did not ﬁnd a signiﬁcant treatment
moderation effect of these or other measured covariates.
The ﬁndings raise important issues for future research,
but from a clinical viewpoint they provide unique new
evidence on the beneﬁt of treating cigarette addiction with
pharmacotherapy regardless of smokers’ mental health
status or other demographic and smoking history
characteristics.
Clinical trial registration
Clinical trial registration no. NCT01456936 (https://
clinicaltrials.gov/ct2/show/NCT01456936).
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